cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.1568726
title: Glacial geomorphology of the Maidika region, Tibetan Plateau

description: We present a glacial geomorphological map at a scale of 1:200,000 of the Maidika region in the southeastern part of the central Tibetan Plateau covering 13,600 km<sup>2</sup>. Based on the 90 m resolution SRTM elevation model, the 30 m resolution ASTER GDEM elevation model, and the Landsat ETM+ satellite imagery of 30/15 m resolution, we have mapped glacial valleys, marginal moraines, glacial lineations, and hummocky terrain. Glacial landforms occur frequently and indicate extensive past glaciation with alpine style valley glaciers as well as more extensive ice fields. Of particular interest is the presence of glacial lineation swarms, which is unusual for the Tibetan Plateau glacial landform record. Based on the distribution of glacial landforms, we present a generalized maximum glacial extent reconstruction covering 6045 km<sup>2</sup> or 44% of the map.
DOI: 10.6084/m9.figshare.1568726.v4
title: Glacial geomorphology of the Maidika region, Tibetan Plateau

description: We present a glacial geomorphological map at a scale of 1:200,000 of the Maidika region in the southeastern part of the central Tibetan Plateau covering 13,600 km<sup>2</sup>. Based on the 90 m resolution SRTM elevation model, the 30 m resolution ASTER GDEM elevation model, and the Landsat ETM+ satellite imagery of 30/15 m resolution, we have mapped glacial valleys, marginal moraines, glacial lineations, and hummocky terrain. Glacial landforms occur frequently and indicate extensive past glaciation with alpine style valley glaciers as well as more extensive ice fields. Of particular interest is the presence of glacial lineation swarms, which is unusual for the Tibetan Plateau glacial landform record. Based on the distribution of glacial landforms, we present a generalized maximum glacial extent reconstruction covering 6045 km<sup>2</sup> or 44% of the map.
DOI: 10.6084/m9.figshare.1568726.v3
title: Glacial geomorphology of the Maidika region, Tibetan Plateau

description: ABSTRACTWe present a glacial geomorphological map at a scale of 1:200,000 of the Maidika region in the southeastern part of the central Tibetan Plateau covering 13,600 km<sup>2</sup>. Based on the 90 m resolution SRTM elevation model, the 30 m resolution ASTER GDEM elevation model, and the Landsat ETM+ satellite imagery of 30/15 m resolution, we have mapped glacial valleys, marginal moraines, glacial lineations, and hummocky terrain. Glacial landforms occur frequently and indicate extensive past glaciation with alpine style valley glaciers as well as more extensive ice fields. Of particular interest is the presence of glacial lineation swarms, which is unusual for the Tibetan Plateau glacial landform record. Based on the distribution of glacial landforms, we present a generalized maximum glacial extent reconstruction covering 6045 km<sup>2</sup> or 44% of the map.
DOI: 10.6084/m9.figshare.1568717
title: Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts

description: <i>Purpose</i>: Thrombospondin-1 (TSP-1), a major regulator of cell interaction with the environment, is often deregulated in cancers, including ovarian carcinoma. Both the tumor and the host cells can release TSP-1 in the tumor microenvironment. The relative contribution of the two sources in determining TSP-1 levels in ovarian cancer remains to be elucidated. This study was designed to investigate the expression of tumor TSP-1 in a panel of 29 patient-derived ovarian adenocarcinoma xenografts (PDX), using analytical tools specific for human (tumor-derived) rather than murine (host-derived) TSP-1.<i>Methodology</i>: Human-specific microarray and ELISA were used to measure tumor TSP-1 expression and plasma levels.<i>Results</i>: Tumor-derived TSP-1 was heterogeneously expressed in PDX. Expression was higher in the corresponding original patient's tumor, where stroma-derived TSP-1 is also analyzed, indicating that both the tumor and the host contribute to TSP-1 production. TSP-1 was differentially expressed according to tumor grade, but not affected by p53 expression or mutational status. Findings were confirmed in an external gene expression dataset (101 patients). In a functional enrichment analysis, TSP-1 correlated with genes related to angiogenesis, cell motility, communication and shape. Plasma TSP-1, detectable in 10/11 PDX, was not associated to its expression in the tumor. The possible association of plasma TSP-1 with p53 mutations and response to chemotherapy warrants further investigation.<i>Conclusions</i>: Ovarian carcinoma PDX are a useful tool to investigate the relative contribution of stroma and tumor cells in the production of tumor associated factors, in relation to the tumor behavior, molecular properties and response to therapy.
DOI: 10.6084/m9.figshare.1568717.v2
title: Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts

description: <i>Purpose</i>: Thrombospondin-1 (TSP-1), a major regulator of cell interaction with the environment, is often deregulated in cancers, including ovarian carcinoma. Both the tumor and the host cells can release TSP-1 in the tumor microenvironment. The relative contribution of the two sources in determining TSP-1 levels in ovarian cancer remains to be elucidated. This study was designed to investigate the expression of tumor TSP-1 in a panel of 29 patient-derived ovarian adenocarcinoma xenografts (PDX), using analytical tools specific for human (tumor-derived) rather than murine (host-derived) TSP-1.<i>Methodology</i>: Human-specific microarray and ELISA were used to measure tumor TSP-1 expression and plasma levels.<i>Results</i>: Tumor-derived TSP-1 was heterogeneously expressed in PDX. Expression was higher in the corresponding original patient's tumor, where stroma-derived TSP-1 is also analyzed, indicating that both the tumor and the host contribute to TSP-1 production. TSP-1 was differentially expressed according to tumor grade, but not affected by p53 expression or mutational status. Findings were confirmed in an external gene expression dataset (101 patients). In a functional enrichment analysis, TSP-1 correlated with genes related to angiogenesis, cell motility, communication and shape. Plasma TSP-1, detectable in 10/11 PDX, was not associated to its expression in the tumor. The possible association of plasma TSP-1 with p53 mutations and response to chemotherapy warrants further investigation.<i>Conclusions</i>: Ovarian carcinoma PDX are a useful tool to investigate the relative contribution of stroma and tumor cells in the production of tumor associated factors, in relation to the tumor behavior, molecular properties and response to therapy.
DOI: 10.6084/m9.figshare.1568717.v4
title: Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts

description: <i>Purpose</i>: Thrombospondin-1 (TSP-1), a major regulator of cell interaction with the environment, is often deregulated in cancers, including ovarian carcinoma. Both the tumor and the host cells can release TSP-1 in the tumor microenvironment. The relative contribution of the two sources in determining TSP-1 levels in ovarian cancer remains to be elucidated. This study was designed to investigate the expression of tumor TSP-1 in a panel of 29 patient-derived ovarian adenocarcinoma xenografts (PDX), using analytical tools specific for human (tumor-derived) rather than murine (host-derived) TSP-1.<i>Methodology</i>: Human-specific microarray and ELISA were used to measure tumor TSP-1 expression and plasma levels.<i>Results</i>: Tumor-derived TSP-1 was heterogeneously expressed in PDX. Expression was higher in the corresponding original patient's tumor, where stroma-derived TSP-1 is also analyzed, indicating that both the tumor and the host contribute to TSP-1 production. TSP-1 was differentially expressed according to tumor grade, but not affected by p53 expression or mutational status. Findings were confirmed in an external gene expression dataset (101 patients). In a functional enrichment analysis, TSP-1 correlated with genes related to angiogenesis, cell motility, communication and shape. Plasma TSP-1, detectable in 10/11 PDX, was not associated to its expression in the tumor. The possible association of plasma TSP-1 with p53 mutations and response to chemotherapy warrants further investigation.<i>Conclusions</i>: Ovarian carcinoma PDX are a useful tool to investigate the relative contribution of stroma and tumor cells in the production of tumor associated factors, in relation to the tumor behavior, molecular properties and response to therapy.
DOI: 10.6084/m9.figshare.1568717.v3
title: Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts

description: <i>Purpose</i>: Thrombospondin-1 (TSP-1), a major regulator of cell interaction with the environment, is often deregulated in cancers, including ovarian carcinoma. Both the tumor and the host cells can release TSP-1 in the tumor microenvironment. The relative contribution of the two sources in determining TSP-1 levels in ovarian cancer remains to be elucidated. This study was designed to investigate the expression of tumor TSP-1 in a panel of 29 patient-derived ovarian adenocarcinoma xenografts (PDX), using analytical tools specific for human (tumor-derived) rather than murine (host-derived) TSP-1.<i>Methodology</i>: Human-specific microarray and ELISA were used to measure tumor TSP-1 expression and plasma levels.<i>Results</i>: Tumor-derived TSP-1 was heterogeneously expressed in PDX. Expression was higher in the corresponding original patient's tumor, where stroma-derived TSP-1 is also analyzed, indicating that both the tumor and the host contribute to TSP-1 production. TSP-1 was differentially expressed according to tumor grade, but not affected by p53 expression or mutational status. Findings were confirmed in an external gene expression dataset (101 patients). In a functional enrichment analysis, TSP-1 correlated with genes related to angiogenesis, cell motility, communication and shape. Plasma TSP-1, detectable in 10/11 PDX, was not associated to its expression in the tumor. The possible association of plasma TSP-1 with p53 mutations and response to chemotherapy warrants further investigation.<i>Conclusions</i>: Ovarian carcinoma PDX are a useful tool to investigate the relative contribution of stroma and tumor cells in the production of tumor associated factors, in relation to the tumor behavior, molecular properties and response to therapy.
DOI: 10.6084/m9.figshare.1568704
title: The investigation of systolic and diastolic leaflet kinematics of bioprostheses with a new <i>in-vitro</i> test method

description: <b>Objectives:</b> We aimed to investigate leaflet kinematics of bioprostheses with a novel high-speed imaging method. <b>Material and methods:</b> High-speed-imaging (1000Hz) was used to evaluate leaflet kinematics of the Carpentier-Edwards Perimount Magna (PM) and Magna Ease (PME) aortic bioprostheses. Both prostheses (diameter 23 mm) were placed inside a model aorta under pulsatile flow conditions. Frequencies (F) and different stroke volumes (S) were simulated. Maximum aortic valve area (AVA), total ejection time (TET), rapid valve opening time (RVOT) and rapid valve closing time (RVCT) as well as opening (OS) and closing (CS) speeds were evaluated. <b>Results</b>: Both bioprostheses showed different results dependent on flow conditions. The test setup was capable of identifying small AVA-differences between both valves (235 vs 202 mm², F60/S60; 272 vs 207 mm²; F70/S80), as well as differences in OS and CS (2.36 vs 1.62 mm²/ms; 2.97 vs 2.44 mm²/ms, F80/S60). TET was comparable (638 vs 645 ms F60/S60; 341 vs 343 ms, F90/S60), while results for RVOT and RVCT were equal, and dependent on frequency and stroke volume. <b>Conclusions</b>: The novel evaluation method is sensitive to detect differences between valves, although differences were found to be small. PM has a larger visible AVA associated with higher opening and closing speeds in contrast to PME.
DOI: 10.6084/m9.figshare.1568704.v1
title: The investigation of systolic and diastolic leaflet kinematics of bioprostheses with a new <i>in-vitro</i> test method

description: <b>Objectives:</b> We aimed to investigate leaflet kinematics of bioprostheses with a novel high-speed imaging method. <b>Material and methods:</b> High-speed-imaging (1000Hz) was used to evaluate leaflet kinematics of the Carpentier-Edwards Perimount Magna (PM) and Magna Ease (PME) aortic bioprostheses. Both prostheses (diameter 23 mm) were placed inside a model aorta under pulsatile flow conditions. Frequencies (F) and different stroke volumes (S) were simulated. Maximum aortic valve area (AVA), total ejection time (TET), rapid valve opening time (RVOT) and rapid valve closing time (RVCT) as well as opening (OS) and closing (CS) speeds were evaluated. <b>Results</b>: Both bioprostheses showed different results dependent on flow conditions. The test setup was capable of identifying small AVA-differences between both valves (235 vs 202 mm², F60/S60; 272 vs 207 mm²; F70/S80), as well as differences in OS and CS (2.36 vs 1.62 mm²/ms; 2.97 vs 2.44 mm²/ms, F80/S60). TET was comparable (638 vs 645 ms F60/S60; 341 vs 343 ms, F90/S60), while results for RVOT and RVCT were equal, and dependent on frequency and stroke volume. <b>Conclusions</b>: The novel evaluation method is sensitive to detect differences between valves, although differences were found to be small. PM has a larger visible AVA associated with higher opening and closing speeds in contrast to PME.
DOI: 10.6084/m9.figshare.1568683
title: Increased risk of male cancer and identification of a potential prostate cancer cluster region in <i>BRCA2</i>

description: <b>Background.</b> The risk of cancer in men from <i>BRCA1</i> and <i>BRCA2</i> families is relevant to define to motivate genetic testing and optimize recommendations for surveillance. <b>Material and methods.</b> We assessed the risk of cancer in male mutation carriers and their first-degree relatives in 290 <i>BRCA1</i> and <i>BRCA2</i> families with comparison to matched controls with the aim to motivate genetic testing and optimize recommendations for surveillance. <b>Results.</b> Mutation carriers in <i>BRCA1</i> families were not at increased risk of cancer, whereas mutation carriers in <i>BRCA2</i> families were at increased risk of male breast cancer and prostate cancer with cumulative risks of 12.5% and 18.8%, respectively. Breast cancer developed at a mean age of 59 years, typically as ER/PR positive ductal carcinomas. Prostate cancer developed at a mean age of 68 years, with Gleason scores ≥ 8 in 40% of the tumors. The hazard ratio for <i>BRCA2</i>-associated prostate cancer was 3.7 (p &lt; 0.001) in mutation carriers and 3.1 (p = 0.001) in first-degree relatives. Of the 37 prostate cancers, 19 were linked to four <i>BRCA2</i> mutations within a region defined by c.6373-c.6492. Individuals with mutations herein had a HR of 3.7 for prostate cancer compared to individuals with mutations outside of this region. <b>Conclusions</b>. Male mutation carriers and first-degree relatives in <i>BRCA2</i> families are at an increased risk of breast cancer and prostate cancer with a potential prostate cancer cluster region within exon 11 of <i>BRCA2.</i>
DOI: 10.6084/m9.figshare.1568683.v2
title: Increased risk of male cancer and identification of a potential prostate cancer cluster region in <i>BRCA2</i>

description: <b>Background.</b> The risk of cancer in men from <i>BRCA1</i> and <i>BRCA2</i> families is relevant to define to motivate genetic testing and optimize recommendations for surveillance. <b>Material and methods.</b> We assessed the risk of cancer in male mutation carriers and their first-degree relatives in 290 <i>BRCA1</i> and <i>BRCA2</i> families with comparison to matched controls with the aim to motivate genetic testing and optimize recommendations for surveillance. <b>Results.</b> Mutation carriers in <i>BRCA1</i> families were not at increased risk of cancer, whereas mutation carriers in <i>BRCA2</i> families were at increased risk of male breast cancer and prostate cancer with cumulative risks of 12.5% and 18.8%, respectively. Breast cancer developed at a mean age of 59 years, typically as ER/PR positive ductal carcinomas. Prostate cancer developed at a mean age of 68 years, with Gleason scores ≥ 8 in 40% of the tumors. The hazard ratio for <i>BRCA2</i>-associated prostate cancer was 3.7 (p &lt; 0.001) in mutation carriers and 3.1 (p = 0.001) in first-degree relatives. Of the 37 prostate cancers, 19 were linked to four <i>BRCA2</i> mutations within a region defined by c.6373-c.6492. Individuals with mutations herein had a HR of 3.7 for prostate cancer compared to individuals with mutations outside of this region. <b>Conclusions</b>. Male mutation carriers and first-degree relatives in <i>BRCA2</i> families are at an increased risk of breast cancer and prostate cancer with a potential prostate cancer cluster region within exon 11 of <i>BRCA2.</i>
DOI: 10.6084/m9.figshare.1568683.v1
title: Increased risk of male cancer and identification of a potential prostate cancer cluster region in <i>BRCA2</i>

description: <b>Background.</b> The risk of cancer in men from <i>BRCA1</i> and <i>BRCA2</i> families is relevant to define to motivate genetic testing and optimize recommendations for surveillance.<b>Material and methods.</b> We assessed the risk of cancer in male mutation carriers and their first-degree relatives in 290 <i>BRCA1</i> and <i>BRCA2</i> families with comparison to matched controls with the aim to motivate genetic testing and optimize recommendations for surveillance.<b>Results.</b> Mutation carriers in <i>BRCA1</i> families were not at increased risk of cancer, whereas mutation carriers in <i>BRCA2</i> families were at increased risk of male breast cancer and prostate cancer with cumulative risks of 12.5% and 18.8%, respectively. Breast cancer developed at a mean age of 59 years, typically as ER/PR positive ductal carcinomas. Prostate cancer developed at a mean age of 68 years, with Gleason scores ≥ 8 in 40% of the tumors. The hazard ratio for <i>BRCA2</i>-associated prostate cancer was 3.7 (p &lt; 0.001) in mutation carriers and 3.1 (p = 0.001) in first-degree relatives. Of the 37 prostate cancers, 19 were linked to four <i>BRCA2</i> mutations within a region defined by c.6373-c.6492. Individuals with mutations herein had a HR of 3.7 for prostate cancer compared to individuals with mutations outside of this region.<b>Conclusions</b>. Male mutation carriers and first-degree relatives in <i>BRCA2</i> families are at an increased risk of breast cancer and prostate cancer with a potential prostate cancer cluster region within exon 11 of <i>BRCA2.</i>
DOI: 10.6084/m9.figshare.1568677
title: Synthesis, Crystal Structure, and Luminescent Property of One 3D Porous Metal-Organic Framework With dmc Topology

description: One new 3D porous metal-organic framework {[Zn(ox)<sub>0.5</sub>(trz)]·0.25H<sub>2</sub>O}<sub><i>n</i></sub> (<b>1</b>) [trz = 1,2,4-triazole, ox = oxalate] has been synthesized under hydrothermal conditions and characterized by elemental analysis, IR spectroscopy, single-crystal X-ray crystallography, and powder X-ray diffraction (PXRD) analysis. The most remarkable structural feature of <b>1</b> is that the assembly of the Zn–trz 2D layers and the ox molecule pillars result in the formation of 3D pillared-layer dmc framework showing porous and helical character. In addition, thermal stability and the luminescent property of the complex have been investigated.
DOI: 10.6084/m9.figshare.1568677.v3
title: Synthesis, Crystal Structure, and Luminescent Property of One 3D Porous Metal-Organic Framework With dmc Topology

description: One new 3D porous metal-organic framework {[Zn(ox)<sub>0.5</sub>(trz)]·0.25H<sub>2</sub>O}<sub><i>n</i></sub> (<b>1</b>) [trz = 1,2,4-triazole, ox = oxalate] has been synthesized under hydrothermal conditions and characterized by elemental analysis, IR spectroscopy, single-crystal X-ray crystallography, and powder X-ray diffraction (PXRD) analysis. The most remarkable structural feature of <b>1</b> is that the assembly of the Zn–trz 2D layers and the ox molecule pillars result in the formation of 3D pillared-layer dmc framework showing porous and helical character. In addition, thermal stability and the luminescent property of the complex have been investigated.
DOI: 10.6084/m9.figshare.1568677.v2
title: Synthesis, Crystal Structure, and Luminescent Property of One 3D Porous Metal-Organic Framework with dmc Topology

description: One new 3D porous metal-organic framework {[Zn(ox)<sub>0.5</sub>(trz)]·0.25H<sub>2</sub>O}<sub><i>n</i></sub> (1) [trz = 1,2,4-triazole, ox = oxalate] has been synthesized under hydrothermal conditions and characterized by elemental analysis, IR spectroscopy, single-crystal X-ray crystallography and powder X-ray diffraction (PXRD) analysis. The most remarkable structural feature of 1 is that the assembly of the Zn–trz 2D layers and the ox molecule pillars result in the formation of 3D Pillared-layer dmc framework showing porous and helical character. In addition, thermal stability and the luminescent property of the complex have been investigated.
DOI: 10.6084/m9.figshare.12918986
title: Trained algorithms - Large ensemble Testbed - NN

description: Trained algorithms for reconstructing pCO2 of the Large Ensemble Testbed using NN. Files stored in h5 format.
DOI: 10.6084/m9.figshare.12918986.v1
title: Trained algorithms - Large ensemble Testbed - NN

description: Trained algorithms for reconstructing pCO2 of the Large Ensemble Testbed using NN. Files stored in h5 format.
DOI: 10.6084/m9.figshare.1568658
title: The stability of Tenax TA thermal desorption tubes in simulated field conditions on the HAPSITE<sup>®</sup> ER

description: Due to the growing need to monitor aircraft cabin, cockpit and breathing-line air quality, functional assessment of sampling equipment for the specialised field conditions of flight need to be established for both in-flight and ground safety. In this article, we assess the reliability of Tenax TA thermal desorption tubes to perform under various relevant field sampling conditions, such as storage temperature, loading temperature, vibrational velocity, gravitational force (G Force) and altitude pressure with semi-real-time gas chromatograph-mass spectrometer (GC-MS) analysis on the field portable HAPSITE<sup>®</sup> ER (Hazardous Air Pollutants on Site Extended Range) instrument. First, we show that Tenax TA thermal desorption tubes can handle storage under extreme environmental conditions, 4–77°C, over numerous analytical test cycles. Next, we confirm that extreme loading temperature, both hot (77°C) and cold (4°C), does not affect the analytical reliability of Tenax TA thermal desorption tubes. Then, we illustrate that G Force may have a significant (<i>p</i> ≤ 0.0364) effect on Tenax TA performance while vibrational velocity (<i>p</i> ≤ 0.7265) and low ambient air pressure (<i>p</i> ≤ 0.1753), such as that found at high altitude, do not. Finally, several Tenax TA thermal desorption tubes were flight-tested, demonstrating that the durability of these tubes maybe insufficient for use on military cargo aircraft (<i>p</i> = 0.0107). The results presented here provide a rationale for additional testing of Tenax TA thermal desorption tubes for flight suitability.